Abstract
The aim of the study was to investigate the use of granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjunctive treatment for clinically refractory mucosal candidiasis in patients with advanced AIDS. Three patients with advanced AIDS and oropharyngeal candidiasis clinically refractory to azoles or amphotericin B received GM-CSF for 14 days along with either fluconazole or amphotericin B. All three patients showed clinical improvement and mycological improvement without any adverse events. Thus, GM-CSF may be a possible alternative as adjunctive therapy in the management of refractory mucosal candidiasis in patients with advanced AIDS.
Publication types
-
Case Reports
-
Clinical Trial
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy*
-
Anti-HIV Agents / therapeutic use
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / pharmacology
-
Antifungal Agents / therapeutic use
-
Candida / drug effects
-
Candida / isolation & purification
-
Candida albicans / drug effects
-
Candida albicans / isolation & purification
-
Candidiasis, Oral / drug therapy*
-
Drug Therapy, Combination
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Microbial Sensitivity Tests
-
Oropharynx / microbiology
-
Pilot Projects
-
Recombinant Proteins
Substances
-
Anti-HIV Agents
-
Antifungal Agents
-
Recombinant Proteins
-
Granulocyte-Macrophage Colony-Stimulating Factor